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Abstract
Mild hyperhomocysteinemia is a risk factor for many diseases, including cardiovascular disease. We
determined the effects of insulin resistance and of type 2 diabetes on homocysteine (Hcy) metabolism
using Zucker diabetic fatty rats (ZDF/Gmi fa/fa and ZDF/Gmi fa/?). Plasma total Hcy was reduced
in ZDF fa/fa rats by 24% in the pre-diabetic insulin-resistant stage, while in the frank diabetic stage
there was a 59% reduction. Hepatic activities of several enzymes that play a role in the removal of
Hcy: cystathionine β-synthase (CBS), cystathionine γ-lyase, and betaine:Hcy methyltransferase
(BHMT) were increased as was methionine adenosyltransferase. CBS and BHMT mRNA levels and
the hepatic level of S-adenosylmethionine were also increased in the ZDF fa/fa rats. Studies with
primary hepatocytes showed that Hcy export and the transsulfuration flux in cells from ZDF fa/fa
rats were particularly sensitive to betaine. Interestingly, liver betaine concentration was found to be
significantly lower in the ZDf fa/fa rats at both 5 and 11 weeks. These results emphasize the
importance of betaine metabolism in determining plasma Hcy levels in type 2 diabetes.
Patients with coronary, cerebrovascular, or peripheral arterial disease have mean plasma total
homocysteine (tHcy) levels significantly higher than control subjects (1). Over the last decade,
these findings led to the identification of hyperhomocysteinemia as an independent risk factor
for vascular disease (1). In addition, hyperhomocysteinemia has also been identified as a risk
factor for Alzheimer's disease (2) and osteoporotic fractures (3).
Homocysteine (Hcy) is formed after the donation of a methyl group from S-
adenosylmethionine (SAM). It can then be metabolized by one of three enzymes. Methionine
synthase and betaine:Hcy methyltransferase (BHMT) catalyze the remethylation of Hcy to
methionine, and cystathionine β-synthase (CBS) forms part of the transsulfuration pathway
where Hcy condenses with serine to form cystathionine. Figure 1 shows the pathway of
methionine metabolism.
Diabetes, whether type 1 or type 2, is associated with an increased risk of cardiovascular
mortality, with the prevalence of atherosclerosis being two- to sixfold higher in diabetic patients
than in people without diabetes (4). Insulin resistance, which immediately precedes the
development of type 2 diabetes, is also associated with an increased risk of coronary artery
disease (5). Hyperhomocysteinemia has been shown to be a stronger risk factor for
cardiovascular disease and for mortality in patients with type 2 diabetes than in subjects without
diabetes (6).
Plasma tHcy in diabetic patients is known to be dependent on the presence or absence of
nephropathy. Both type 1 and type 2 diabetic patients with nephropathy have elevated levels
of tHcy (6,7). However, type 1 diabetic patients with no renal complications have plasma tHcy
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levels lower than controls (8). This decrease was also shown in an animal model of type 1
diabetes (9).
We, therefore, examined the effect of insulin resistance and type 2 diabetes on plasma tHcy
and its metabolism in the liver. We used the leptin receptor–defective Zucker diabetic fatty rat
(ZDF), an excellent model for type 2 diabetes (10). Before developing frank diabetes, they go
through a phase of insulin resistance, thereby giving us an opportunity to study the effects of
both insulin resistance and of type 2 diabetes.
RESEARCH DESIGN AND METHODS
Animals and tissue sampling
All procedures were approved by Memorial University's Institutional Animal Care Committee.
Male ZDF rats (ZDF/Gmi fa/fa) aged 5 and 11 weeks and male lean rats (ZDF/Gmi fa/?) of
the same ages were obtained from Charles River Laboratories, Indianapolis, Indiana. They
were fed Purina 5008 chow ad libitum and had free access to water. On the day of the
experiment, animals were anesthetized with an intraperitoneal injection of sodium
pentobarbital (65 mg/kg), and blood was collected from the abdominal aorta into heparinized
syringes. Before removal of the syringe, a piece of the liver was rapidly removed and freeze-
clamped with aluminum tongs precooled in liquid nitrogen. Another portion was removed for
immediate enzyme assays. The freeze-clamped liver was stored at −70°C until further use. The
blood was centrifuged at 3,700g for 15 min, and the plasma was kept at −20°C until further
use.
Analytical procedures
Plasma metabolites—Plasma tHcy was measured as described (11). Plasma glucose was
determined enzymatically (12). Plasma creatinine was measured using a kit (catalog no. 555A)
from Sigma Diagnostics (St. Louis, MO). Plasma insulin was measured with a rat insulin
enzyme-linked immunosorbent assay kit (catalog no. INSKR020) from Crystal Chem
(Chicago, IL) using anti-rat/mouse insulin antibody and a rat insulin standard.
Enzyme assays
Fresh liver samples were diluted 1:5 with 50 mmol/l K phosphate buffer (pH 7.0) and
homogenized with a Polytron (Brinkman Instruments, Toronto, Canada) for 20 s at 50% output.
The homogenates were centrifuged at 20,000g for 30 min at 4°C, and the supernatant was
removed and used immediately to measure the activities of five of the enzymes of methionine
metabolism. Methionine adenosyltransferase (MAT) (13,14), CBS (13,15), cystathionine γ-
lyase (CGL) (16), methionine synthase (17), and BHMT (18) were assayed using previously
described methods. Methylenetetrahydrofolate reductase (MTHFR) (19) and glycine N-
methyltransferase (GNMT) (20) were measured using previously frozen liver tissue. Choline
dehydrogenase was measured using liver homogenates (21,22). Protein concentrations were
determined by the Biuret method using BSA as a standard. All enzyme assays were determined
to be linear with time and with protein.
Liver metabolites
Choline and its metabolites were extracted from tissue and plasma by the method of Bligh and
Dyer (23). Aqueous and organic compounds were separated, analyzed, and quantified directly
by high-performance liquid chromatography–mass spectrometry (liquid chromatography–
electrospray ionization–isotope dilution mass spectrometry) after the addition of internal
standards labeled with stable isotopes that were used to correct for recovery (24). The levels
of SAM and S-adenosylhomocysteine (SAH) were measured in freeze-clamped liver tissue
(25).
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Total RNA was isolated from the fresh liver samples as previously described (26). Two
micrograms of RNA were reverse transcribed using a one-step reverse transcription kit
(Qiagen, Mississauga, Canada) and was amplified by 27 cycles. An upstream primer (5′-
GCCTTCAGGACATCCAGTGT-3′) and a downstream primer (5′-
TCTTTCCGGGTCTGCTCACGGGC-3′) corresponding to the type 3 rat CBS cDNA (27)
were used to amplify a 1,644-bp PCR fragment. For BHMT, an upstream primer (5′-
ACCGATTGCCGGCAAGAA-3′) and a downstream primer (5′-
CTGTGCGGATTTGAATTTTTG-3′) corresponding to the rat BHMT cDNA (NM-030850)
were used to amplify a 1,216-bp PCR fragment. A 768-bp fragment of the rat β-actin was
coamplified using amplimer set primers (CLONTECH, Palo Alto, CA). Once amplified, the
PCR products were separated on 0.8% agarose. The bands were stained with ethidium bromide
and were visualized under UV illumination.
Homocysteine metabolism in isolated hepatocytes
Hepatocytes were isolated from ZDF fa/fa and ZDF fa/? rats (28). Approximately 5 mg of
hepatocytes (dry weight) were preincubated for 20 min at 37°C with Krebs-Henseleit saline
with or without 0.3 mmol/l betaine. At the end of the preincubation L-[1-14C] methionine was
added to a final concentration of 0.1 mmol/l and the incubation continued for a further 30 min.
The total transsulfuration flux was determined as the sum of the 14C present in α-ketobutyrate
and in CO2 as previously described (29). In a separate series of experiments, hepatocytes were
incubated with 0.1 mmol/l methionine ± 0.3 mmol/l betaine to measure Hcy export (29).
Statistical analysis
Data are presented as means ± SD. Means were compared using Student's unpaired t test, paired
t test, or one-way ANOVA as appropriate. P < 0.05 was taken to indicate a significant
difference.
RESULTS
The body weight, hepatosomatic index, plasma insulin, creatinine, and glucose concentrations
of these rats have been reported (30). At 5 weeks, the concentrations of plasma glucose (12.1
± 1.7 vs. 8.4 ± 1.3 mmol/l) and insulin (1.5 ± 0.5 vs. 0.14 ± 0.07 nmol/l) in the ZDF fa/fa and
ZDF fa/? rats, respectively, showed that the ZDF fa/fa rats had become insulin resistant. At 11
weeks, the concentrations of plasma glucose (30.3 ± 1.6 vs. 10.9 ± 0.8 mmol/l) and insulin
(0.61 ± 0.14 vs. 0.68 ± 0.1 nmol/l) in the ZDF fa/fa and the ZDF fa/? rats, respectively, showed
that the ZDF fa/fa rats had become diabetic. Creatinine levels of ZDF fa/fa and control rats at
5 weeks were similar (32.4 ± 3.8 vs. 28.9 ± 3.1 μmol/l), but at 11 weeks were lower in the ZDF
fa/fa rats (18.9 ± 2.7 vs. 29.7 ± 6.1 μmol/l)
Plasma Hcy and hepatic enzymes of Hcy metabolism
At 5 weeks, plasma tHcy was about 25% lower in the ZDF fa/fa rats, while at 11 weeks it was
reduced by about 60% (Table 1). The plasma tHcy level in the ZDF fa/fa rats at 11 weeks was
further reduced from its value at 5 weeks, whereas the ZDF fa/? rats showed an increase in the
plasma tHcy level with age. The reduced plasma tHcy at 5 weeks in the ZDF fa/fa rats was
accompanied by changes in several enzymes that metabolize methionine (Table 1). Of the
enzymes responsible for producing Hcy, MAT and GNMT showed slight but significant
increases. CBS, CGL, BHMT, and MTHFR were increased, respectively, by about 79, 35, 80,
and 22%. Methionine synthase showed a slight but significant decrease in the ZDF fa/fa rats.
At 11 weeks, MAT, GNMT, CBS, CGL, and BHMT all showed significant increases in activity
as did choline dehydrogenase.
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In addition to the differences in enzyme activity between the control and the experimental
animals at each age-group, MAT, CBS, and GNMT all showed significant increases in their
activity with age in the ZDF fa/? rats.
mRNA levels
At 5 weeks, the increased activity of CBS in the ZDF fa/fa rats was accompanied by a
comparable increase in CBS mRNA level (Fig. 2A). The increased BHMT activity observed
in the ZDF fa/fa rats at 5 and 11 weeks was also accompanied by comparable increases in
mRNA levels (Fig. 2B).
SAM, SAH, and SAM-to-SAH ratio
The hepatic levels of SAM and SAH and the SAM-to-SAH ratio are shown in Table 2. At both
5 and 11 weeks, SAM was significantly increased in the ZDF fa/fa rats. The SAM-to-SAH
ratio was significantly higher in the ZDF fa/fa rats at 5 weeks. Both SAM and the SAM-to-
SAH ratio showed increases with age in ZDF fa/? rats, consistent with the age-related increase
in MAT activity.
Transsulfuration flux
In a preliminary study, we investigated the effect of betaine on the transsulfuration flux, as
measured by the conversion of L-[1-14C] methionine to 14CO2 and 14C-α-ketobutyrate by
isolated hepatocytes from Sprague Dawley rats. All concentrations of betaine used (0.1, 0.3,
or 1 mmol/l) significantly reduced the catabolism of methionine, compared with incubations
of hepatocytes with methionine alone. We then conducted studies with hepatocytes from ZDF
rats using 0.1 mmol/l L-[1-14C] methionine and 0.3 mmol/l betaine. Incubation with 0.3 mmol/
l betaine significantly decreased the transsulfuration flux in hepatocytes of ZDF fa/fa rats at
both ages, but the reduction seen in the hepatocytes of ZDF fa/? rats was significant only at 11
weeks of age (Table 3).
Hcy export
Hepatocytes from ZDF fa/fa and ZDF fa/? rats, at both ages, showed a significant reduction
in Hcy export when incubated with 0.3 mmol/l betaine (Table 4). However, at both ages the
decrease observed in the ZDF fa/fa rats was about twofold greater than that of the ZDF fa/?
rats.
Choline and related metabolites
Table 5 shows the liver concentrations of choline and related metabolites. The liver betaine
concentration was lower in the ZDF fa/fa rats at both 5 and 11 weeks, while there was no
difference in the choline concentration. One of the most remarkable findings was the high level
of betaine found in the liver of the young animals and the reduction that occurs with age. Hepatic
glycerophosphorylcholine was significantly higher in the ZDF fa/fa rats at 5 weeks, though at
11 weeks it was significantly lower. Phosphorylcholine was significantly higher in the ZDF
fa/fa rats at both ages. Both glycerophosphorylcholine and phosphorylcholine levels increased
with age in the ZDF fa/? rats. Phosphatidylcholine was significantly decreased in ZDF fa/fa
rats at 11 weeks, while sphingomyelin was significantly reduced at both 5 and 11 weeks.
Table 6 shows choline and related metabolite concentrations in the plasma. The only significant
difference in plasma metabolites between the different rats was an increased
phosphatidylcholine level in the ZDF fa/fa rats at 11 weeks. However, the plasma betaine
concentration decreased with age in both groups of rats while the concentration of
phosphatidylcholine increased in the ZDF fa/fa rats from 5 to 11 weeks.
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This study describes the altered metabolism of methionine and Hcy that occurs in insulin
resistance and in early type 2 diabetes. It is clear that the hormonal changes that are prevalent
in these two disease states act at several sites in the pathway of methionine metabolism.
Hyperphagia in the diabetic rats may also contribute to these metabolic changes. Indeed, we
observed a twofold increase in food intake per 100 g body weight at the diabetic stage.
However, there was no difference at 5 weeks. The increased hepatic CBS and BHMT activity
at 5 weeks cannot, therefore, be attributed to increased protein intake. In addition, we have
shown a direct effect of insulin in repressing CBS expression in both human and rat cultured
hepatocytes (42). Our finding of lowered plasma tHcy in the 5-week ZDF fa/fa rats shows that
insulin resistance alone can decrease plasma tHcy levels.
The most striking finding in the present study concerns the role of betaine and BHMT in
determining plasma tHcy. Not only was BHMT activity and mRNA levels elevated but the
hepatic betaine concentration was remarkably reduced. Furthermore, this increased BHMT
was clearly effective in decreasing hepatic Hcy output. This is evident from the data showing
that addition of betaine to hepatocytes from ZDF fa/fa rats virtually eliminated Hcy export
from cells compared with a lesser effect in hepatocytes from ZDF fa/? rats (Table 4). Increased
remethylation of Hcy by BHMT also reduces the Hcy available for flux through the
transsulfuration pathway, which decreased in these cells (Table 3). Although the importance
of the BHMT-catalyzed remethylation reaction in determining Hcy levels has not received as
much attention as the folate-dependent remethylation pathway, it should be recalled that
Schwahn et al. (31) found a highly significant negative correlation between plasma betaine and
plasma tHcy concentrations in humans. Supplementation with betaine was shown to lower
plasma tHcy in humans (32) and in MTHFR +/+, +/−, and −/− mice (31). Because of the elevated
BHMT activity, betaine may be particularly efficacious in reducing plasma tHcy in the later
stages of type 2 diabetes when renal complications bring about hyperhomocysteinemia.
Our data suggest that there is enhanced utilization of betaine in the ZDF fa/fa rat. The observed
decrease in hepatic phosphatidylcholine concentration (Table 5) is consistent with enhanced
utilization of choline to form betaine in the livers of these rats. Sphingomyelin, which is derived
from phosphatidylcholine, is also reduced in fa/fa liver. The increase in phosphorylcholine
concentrations may reflect increased activity of the pathway for phosphatidylcholine
biosynthesis that occurs when tissue phosphatidylcholine concentrations fall. The significant
increase in plasma phosphatidylcholine concentrations in ZDF fa/fa rats at 11 weeks (Table 6)
probably reflects increased secretion of lipoproteins from liver.
Another remarkable feature of betaine metabolism is the extraordinarily high hepatic betaine
concentration found in young rats. In the control animals (ZDF fa/?), the hepatic betaine level
was 17.6 μmol/g at 5 weeks; this decreased to 5.3 μmol/g at 11 weeks. Assuming that hepatic
betaine is evenly distributed in intracellular water and that rat liver contains 0.45 ml of cell
water per gram (35), we can calculate a betaine concentration in the 5-week-old control animals
of 39 mmol/l. This should be compared with total osmolarity of about 305−310 mOs mmol/l
in mammalian tissues (except for the renal medulla).
Davies et al. (36) have reported a very large urinary excretion of betaine in normal neonates
and in young rats after weaning. High betaine concentrations are found in mammalian kidneys,
particularly in the renal medulla. Renal betaine has been characterized as a compatible osmolyte
(together with other trimethylamines and polyols) where it can offset the high extracellular
osmolarity that arises as a result of the urinary concentrating mechanisms. In addition, these
osmolytes may protect these cells from adverse effects of urea, which is present at high
concentrations (37).
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Wettstein et al. (38) have showed that betaine plays a role in cell volume homeostasis in
perfused livers of adult rats. Whether this is also the function of the high betaine concentrations
in neonatal liver is a focus of our current work. We must also comment on the ratio of
hepatocellular to plasma betaine. Plasma betaine was fairly constant, in the 90−170 μmol/l
range, in all of the rats (Table 6). The liver-to-plasma concentration ratios for betaine were
about 230, 130, 100, and 60, respectively, for ZDF fa/? and ZDF fa/fa rats at 5 and 11 weeks
of age. How such gradients are produced and maintained are important issues for future work.
Diabetes is characterized not only by the lack of insulin or the resistance to the action of insulin,
but also by increases in the counter-regulatory hormones glucocorticoid and glucagon (39,
40). Hepatic MAT activity has been shown to be increased by glucocorticoid administration
(41). Finkelstein et al. (33) examined the effects of administration of a number of hormones
on BHMT activity. The principal findings were that hydrocortisone increased BHMT activity,
whereas thyroxin decreased it. This group also demonstrated increased activity in alloxan
diabetic rats. This latter finding has been confirmed by Nieman et al. (34) in streptozotocin-
induced diabetic rats. We are currently exploring the possibility that insulin may regulate
BHMT expression. Insulin treatment of streptozotocin-induced diabetic rats was shown to
restore the increased activity of CBS to normal levels (9) by acting at the level of CBS gene
transcription to repress CBS promoter activity (42). Cyclic AMP, the intracellular messenger
of glucagon, and glucocorticoids increase CBS expression in rat hepatoma cells (43). The
increased activity of CBS, brought about both by allosteric activation by the increased hepatic
SAM levels (44) and by increased expression, does not imply an increased transsulfuration
flux. This flux is determined by the rate at which methionine enters into hepatic metabolism,
which will be largely determined by dietary methionine consumption. It seems that the major
effect of increased CBS activity is to decrease the steady-state Hcy concentration at which
transsulfuration occurs (45). In this way it contributes to the decreased plasma tHcy
concentration. Similarly, the increased activity of BHMT does not necessarily imply an
increased remethylation flux in vivo but, rather, it decreases the steady-state Hcy concentration
at which remethylation via BHMT occurs.
It is also possible that alterations in renal function may contribute, somewhat, to the decreased
plasma tHcy, at least when the rats are diabetic. The kidney is a major site for the removal and
subsequent metabolism of Hcy (46). Hyperfiltration is a characteristic sign of renal dysfunction
in early diabetes (47). Such hyperfiltration has been reported to occur in ZDF fa/fa rats from
about 7 weeks of age and to continue until they are about 3 months old (48). Such an occurrence
probably accounts for the decreased plasma creatinine seen at 11 weeks. The delivery of an
increased quantity of Hcy to the kidney via filtration could result in increased renal catabolism
of Hcy and contribute to its reduced plasma concentration. However, this cannot contribute to
the decreased Hcy at the insulin-resistant stage where creatinine levels were unchanged.
It is now clear that plasma tHcy levels decrease in both type 1 and type 2 diabetes when there
is no renal damage. The present work showed that this is true even at the prediabetic, insulin-
resistant stage. However, literature reports on the phenomenon show a variety of responses of
Hcy to insulin resistance (5,49,50). This variability is likely to result from different degrees of
insulin resistance as well as other factors such as impaired renal function. Our results, which
at 5 weeks were obtained in an animal model in which there was no evidence of impaired renal
function as well as a consistent degree of insulin resistance, agree remarkably well with
Rosolova's study of the relationship between Hcy and insulin resistance in healthy human
subjects (5).
In summary, this study shows a decreased plasma tHcy level in both insulin-resistant and type
2 diabetic rats. We show increased activities of BHMT and CBS in these states, as well as
increased mRNA levels for these enzymes. We also show increased hepatic SAM levels, which
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will activate CBS. We report experiments in hepatocytes that directly demonstrate the role of
betaine metabolism in enhanced Hcy removal. These results emphasize the importance of
BHMT in regulating Hcy metabolism.
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RT-PCR analysis of gepatic cystathionine β-synthase mRNA (A) and BHMT mRNA (B). The
relative amounts of each mRNA, measured by spot densitometry, are graphically represented.
Both CBS and BHMT mRNA were normalized to β-actin mRNA. Values are means ± SD for
six rats. Differing superscripts at each age-group indicate significant difference from each
other. P < 0.05.
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TABLE 1
Plasma total homocysteine and hepatic activities of enzymes of homocysteine metabolism
5 weeks 11 weeks
ZDF fa/? ZDF fa/fa ZDF fa/? ZDF fa/fa
Plasma total homocysteine (μmol/l) 4.8 ± 0.5a 3.6 ± 0.2b 7.5 ± 0.4a 3.1 ± 0.3b
MAT 0.49 ± 0.02a 0.6 ± 0.04b 1.3 ± 0.09a 1.7 ± 0.09b
CBS 3.9 ± 0.4a 7.0 ± 1.0b 6.3 ± 0.9a 11.2 ± 1.9b
GNMT 0.52 ± 0.06a 0.73 ± 0.04b 0.67 ± 0.08a 1.0 ± 0.09b
CGL 16.5 ± 2.3a 22.3 ± 2.8b 16.5 ± 1.4a 38.4 ± 4.2b
Methionine synthase 0.033 ± 0.002a 0.029 ± 0.002b 0.032 ± 0.003 0.035 ± 0.003
MTHFR 0.09 ± 0.01a 0.11 ± 0.01b 0.09 ± 0.02 0.1 ± 0.02
BHMT 0.4 ± 0.04a 0.72 ± 0.06b 0.34 ± 0.06a 0.76 ± 0.08b
Choline dehydrogenase 2.7 ± 0.5 3.2 ± 0.7 2.4 ± 0.4a 3.1 ± 0.6b
Data are means ± SD for six rats. In each group, enzyme activities are expressed as micromoles of product synthesized per minute per 100 g body weight.
Differences in superscript letters signify significant differences within each age-group (P < 0.05).
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TABLE 2
SAM, SAH, and hepatic SAM-to-SAH ratio
5 weeks 11 weeks
ZDF fa/? ZDF fa/fa ZDF fa/? ZDF fa/fa
SAM 88 ± 8.4a 142.1 ± 11.3b 172.9 ± 20.0a 199.9 ± 15.5b
SAH 12.3 ± 1.2 11.6 ± 1.3 11.9 ± 2.3 11.7 ± 2.2
SAM-to-SAH 7.2 ± 0.7a 12.3 ± 2.0b 15.1 ± 4.7 17.5 ± 3.5
Data are means ± SD for six rats in each group, and values for SAM and SAH are expressed as nmol/g liver. At each age-group, differences in superscript
letters indicate significant difference from the ZDF fa/? rats (P < 0.05).
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TABLE 3
Transsulfuration flux in isolated hepatocytes
Transsulfuration flux (nmol · mg dry wt−1 · 30 min−)
5 weeks 11 weeks
ZDF fa/? ZDF fa/fa ZDF fa/? ZDF fa/fa
L-[1-14C] methionine 1.00 ± 0.25 1.08 ± 0.05 1.18 ± 0.21 1.08 ± 0.15
L-[1-14C] methionine + betaine 0.91 ± 0.32 0.87 ± 0.12* 0.96 ± 0.15* 0.86 ± 0.13*
Data are means ± SD; n = 3 for 5 weeks and n = 5 for 11 weeks. Hepatocytes were incubated with 0.1 mmol/l L-[1-14C] methionine ± 0.3 mmol/l betaine
to determine the transsulfuration flux.
*
Significant difference from the corresponding incubations without betaine (P < 0.05).
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TABLE 4
Homocysteine export from isolated hepatocytes
Homocysteine export (nmol · mg dry wt−1 · 30 min−)
5 weeks 11 weeks
ZDF fa/? ZDF fa/fa ZDF fa/? ZDF fa/fa
Methionine 1.17 ± 0.23 1.21 ± 0.25 1.64 ± 0.61 2.03 ± 0.92
Methionine + betaine 0.86 ± 0.12* 0.52 ± 0.08* 0.89 ± 0.45* 0.32 ± 0.26*
Data are means ± SD; n = 3 for 5 weeks and n = 5 for 11 weeks. Hcy export was measured in hepatocytes isolated from ZDF rats incubated with 0.1 mmol/
l methionine ± 0.3 mmol/l betaine.
*
Significant difference from corresponding incubations without betaine (P < 0.05).
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TABLE 5
Choline and related metabolite concentrations in the liver of ZDF fa/? and ZDF fa/fa rats aged 5 and 11 weeks
5 weeks 11 weeks
Metabolite ZDF fa/? ZDF fa/fa ZDF fa/? ZDf fa/fa
Betaine 17.6 ± 3.6a 9.9 ± 1.4b 5.3 ± 0.7a 2.5 ± 0.7b
Choline 0.06 ± 0.03 0.04 ± 0.01 0.04 ± 0.01 0.03 ± 0.01
Glycerophosphorylcholine 0.6 ± 0.04a 1.0 ± 0.2b 1.5 ± 0.1a 0.96 ± 0.1b
Phosphorylcholine 1.2 ± 0.27a 2.1 ± 0.3b 1.9 ± 0.3a 2.9 ± 0.9b
Phosphatidylcholine 28.1 ± 2.8 29.2 ± 1.4 25.3 ± 5.2a 19.3 ± 2.0b
Sphingomyelin 3.3 ± 0.3a 2.9 ± 0.2b 3.4 ± 0.4a 2.8 ± 0.3b
Data are means ± SD (μmol/g) for six rats. Differences in superscript letters signify a significant difference from the ZDF fa/? rats of the same age (P <
0.05).
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TABLE 6
Choline and related metabolite concentrations in the plasma of ZDF fa/? rats and ZDF fa/fa rats at 5 and 11 weeks of
age
5 weeks 11 weeks
Metabolite ZDF fa/? ZDF fa/fa ZDF fa/? ZDF fa/fa
Betaine 0.17 ± 0.04 0.17 ± 0.02 0.12 ± 0.03 0.09 ± 0.03
Choline 0.08 ± 0.02 0.08 ± 0.03 0.07 ± 0.01 0.08 ± 0.02
Phosphatidylcholine 0.86 ± 0.27 0.95 ± 0.23 0.80 ± 0.29a 1.69 ± 0.48b
Data are means ± SD (μmol/ml). Differences in superscript letters signify a statistically significant difference from the ZDF fa/? rats of the same age (P
< 0.05).
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